Top Stories
The oral small-molecule beta-glucocerebrosidase activator pariceract missed the mark in a Phase IIb study, while John Powers III was tapped to serve as interim head of the NIH's National Institute of Allergy and Infectious Diseases.
The deal with AlzeCure Pharma, worth potentially more than $1 billion, centres on the preclinical gamma-secretase modulator ACD680.
The purchase includes the ROS1 inhibitor zidesamtinib and the ALK inhibitor neladalkib, both of which are under review by the FDA.
A Phase III study testing Trodelvy with Merck & Co.'s Keytruda in first-line lung cancer was discontinued, while the companies' oral once-weekly single-tablet treatment regimen for HIV succeeded in two trials.
The European Commission cleared a subcutaneous version of Sanofi's anti-CD38 mAb Sarclisa, while GNI Group bought Ayumi Pharmaceutical for about $280 million.
Conference News
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
New data from Pfizer's monthly GLP-1 agonist is aimed squarely at Amgen, which has its own plans for cornering the extended dosing marketplace.
Five scientific talks and a new preprint highlighted Nanovial applications across immune-tumor interactions, antibody discovery, and functional screeningLOS ANGELES, June 9, 2026 /PRNewswire/ -- Parti...
Masitinib treatment has been linked to a 5-year survival rate of 42.3% from the onset of the disease, marking a two-fold increase compared to historical standards.In patients with ALS who had not expe...
A single intratumoral injection resulted in no reported skeletal‑related events (SREs) or fracturesNo treatment‑emergent adverse events (AEs) or serious adverse events (SAEs)Cessation of tumor activit...
